If phase III clinical trials are successful, researchers recommend reclassification of the drug psilocybin (which is found in magic mushrooms) from Class A to schedule IV in the USA, which is roughly the equivalent to Class C in New Zealand.
Scientists studying psilocybin suggest removing the psychedelic substance from the most restrictive legal category (the equivalent of Class A in New Zealand). "We want to initiate the conversation now as to how to classify psilocybin to facilitate its path to the clinic and minimize logistical hurdles in the future," says Matthew W. Johnson, Ph.D., associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "We expect these final clearance trials to take place in the next five years or so.”
Should magic mushrooms be re-classified as Class C in New Zealand, the same as sleeping pills? Or are the mushrooms and their active ingredients safer than that? Perhaps they might be more suitable for reclassification under the PSA in New Zealand, as legally available psychoactive substances, sold from licensed outlets. What do you think? Please share your thoughts in the comments section below:
Read more: Science Daily
Source: John Hopkins medicine